"DOI","paper_doi","paper_title_x","count_atlas","Publication_PMID","Publication_link","count_lnpdb","lnp_id","ionizable_lipid","peg_lipid","sterol_lipid","helper_lipid","lipid_molar_ratio","particle_size_nm_std","pdi_std","zeta_potential_mv_std","encapsulation_efficiency_percent_std","loading_capacity_std","target_type","nucleic_acid_sequence","peg_lipid_original","ionizable_lipid_original","helper_lipid_original","sterol_lipid_original","ionizable_lipid_smiles","peg_lipid_smiles","sterol_lipid_smiles","helper_lipid_smiles","synthesis_info","bioactivity_profile","paper_title_y","paper_authors","paper_journal","paper_year","ionizable_lipid_smiles (InChI Code)"
"10.1038/ncomms5277","10.1038/ncomms5277","Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity",3,24969323,"https://www.nature.com/articles/ncomms5277",1273,1027,"Custom lipid","DMG-PEG2000","cholesterol","DSPC","50:1.5:38.5:10",98.2,,12.5,79,"WR:5(wt/wt)[lipidoid:siRNA] to 10:1","siRNA","factor_vii","PEG2000-DMG","306O12 (lipidoid)","DSPC","cholesterol","CCCCCCCCCCCOC(=O)CCN(CCCN(C)CCCN(CCC(=O)OCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCC)CCC(=O)OCCCCCCCCCCCC","CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)OC(=O)CCCCCCCCCCCCC","C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C","CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC","synthesis_method: Microfluidic mixing or pipet mixing; device_used: Microfluidic device or pipet; total_flow_rate_ml_min: ; flow_rate_ratio: 1:1 (lipid solution:siRNA solution); aqueous_phase_composition: 10 mM sodium citrate; organic_phase_composition: 90% ethanol, 10% 10 mM sodium citrate; mixing_time_sec: ; temperature_condition: ; post_processing: diluted in PBS, dialysed against PBS for 90 min in 3,500 MWCO cassettes; sterilization: ; storage_buffer: PBS","cell_line: HeLa cells (firefly and Renilla luciferase); animal_model: Female C57BL/6 mice; administration_route: IV (lateral tail vein injection); dose: 1 mg/kg (EC50); gene_expression_result: >95% Factor VII silencing at 5 mg/kg","Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity","['Kathryn A. Whitehead', 'J. Robert Dorkin', 'Arturo J. Vegas', 'Philip H. Chang', 'Omid Veiseh', 'Jonathan Matthews', 'Owen S. Fenton', 'Yunlong Zhang', 'Karsten T. Olejnik', 'Volkan Yesilyurt', 'Delai Chen', 'Scott Barros', 'Boris Klebanov', 'Tatiana Novobrantseva', 'Robert Langer', 'Daniel G. Anderson']","Nature Communications",2014,"InChI=1S/C66H129N3O8/c1-6-10-14-18-22-26-30-34-38-42-60-75-64(71)48-56-68(55-47-63(70)74-59-41-37-33-29-25-21-17-13-9-4)53-45-51-67(5)52-46-54-69(57-49-65(72)76-61-43-39-35-31-27-23-19-15-11-7-2)58-50-66(73)77-62-44-40-36-32-28-24-20-16-12-8-3/h6-62H2,1-5H3"
